tirzepatide crohn's Efficacy of for weight loss and it's comparative effectiveness to weight loss surgery in inflammatory bowel disease | Indian Journal of Gastroenterology Glucagon-like peptide-1 (GLP-1) receptor agonists

Next-Day Appointments Available

Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications

Do you offer bulk pricing

Quality reporting offers benefits beyond simply satisfying federal requirements

While the specific risk of gallstone formation is not applicable to patients who have already undergone cholecystectomy, other biliary tract complications remain theoretically possible